

DAFTAR PUSTAKA

- Anonim. 2015. NCCN Clinical Practice Guidelines in Oncology, Non-Small Cell Lung Cancer, Version 4.2015. NCCN [serial online][cited 2015 May 04]. Available from: <http://www.nccn.org>
- American Cancer Society. 2014. *Cancer Facts and Figures 2014*. American Cancer Society, Atlanta.
- American Cancer Society. 2016. *Lung Cancer (Non-Small Cell)*. American Cancer Society, Atlanta
- Bootman, J.L., Townsend, R.J., McGhan, W.F., 2005. Principles of Pharmacoeconomics, Third Edition. Harvey Whitney Book Company, Cincinnati.
- Chouaid, C., Crequit, P., Borget, I., Vergnenegre, A., 2014. Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic review. *Clinicoecon Outcomes Res.* 7:9-15.
- Comella, P., Frasci, G., Panza, N., Manzione, L., De Cataldis, G., Cioffi, R., et al., 2000. Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group. *J Clin Oncol.* 18:1451—7.
- Cooke, J., 2003. Pharmacoeconomics, in Walker, R. & Edwards, C., *Clinical Pharmacy and Therapeutics, Third Edition*, 91-97. Churchill Livingstone, London.
- Corner, J., Hopkinson, J., Fitzsimmons, D., Barclay, S., Muers, M., 2005. Is late diagnosis of lung cancer inevitable? Interview study of patients' recollections of symptoms before diagnosis. *Thorax.* 60:314-319.
- Dipiro, J.T., Talbert, R.L., Yee, G.C., Matzke, G.R., Wells, B.G., Posey, L.M., 2008. *Pharmacotherapy: A Pathophysiologic Approach* 7th Ed. McGrawHill, United State.
- Dipiro, J.T., Talbert, R.L., Yee, G.C., Matzke, G.R., Wells B.G., Posey, L.M., 2014. *Pharmacotherapy: A Pathophysiologic Approach* 9th Ed, McGrawHill, United State.
- Ekwueme, D.U., Yabroff, K.R., Guy Jr., G.P., Banegas, M.P., de Moor, J.S., Li, C., Han, X., Zheng, Z., Soni, A., Davidoff, A., Rechis, R., Virgo, K.S., 2014. Medical costs and productivity losses of cancer survivors – United States, 2008-2011. Center for Disease Control and Prevention. *MMWR Morb. Mortal. Wkly. Rep.* 63(23):505-10

- Evans, T.L., 2005. Chemotherapy in Advanced Non-Small Cell Lung Cancer: Optimal Treatment Approach for Elderly and Patients With Poor Performance Status. *Semin Respir Crit Care Med.* 26(3):304-13.
- Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E., Forman, D., 2011. Global cancer statistics. *CA Cancer J. Clin.* 61(2):69-90.
- Kaisaeng, N., Harpe, S.E., Carroll, N.V., 2014. Out-of-pocket costs and oral cancer medication discontinuation in the elderly. *J Manag Care Spec Pharm.* 20(7):669-75
- Kang, S., Koh, E.S., Vinod, S.K., Jalaludin, B., 2012. Cost analysis of lung cancer management in South Western Sydney. *J Med Imaging Radiat Oncol.* 56(2):235-41.
- McCune, J.S., Frieze, D.A., 2008. Lung Cancer, in Dipiro, J.T., Talbert, R.L., Yee, G.C., Matzke, G.R., Wells, B.G., Posey, L.M., *Pharmacotherapy: A Pathophysiologic Approach* 7th Ed, 2157-2173. McGrawHill, United State.
- National Cancer Institute. 2011. The Cost of Cancer. [serial online] [cited 2014 September 26] Available from: <http://www.cancer.gov/aboutnci/servingpeople/understandingburden/costofcancer>.
- Neymark, N., Lianes, P., Smit, E.F., van Meerbeeck, J.P., 2005. Economic evaluation of three two-drug chemotherapy regimens in advanced non-small-cell lung cancer. *Pharmacoeconomics.* 23(11):1155–1166.
- Novello, S., Kielhorn, A., Stynes, G., Selvaggi, G., De Marinis, F., Maestri, A., Foggi, P., Tilden, D., Tonato, M., Crinò, L., Rinaldi, M., Migliorino, A.M., Scagliotti, G.V., 2005. Cost-minimisation analysis comparing gemcitabine/cisplatin, paclitaxel/carboplatin and vinorelbine/cisplatin in the treatment of advanced non-small cell lung cancer in Italy. *Lung Cancer.* 48(3):379-87.
- Pimentel, F.L., Bhalla, S., Laranjeira, L., Guerreiro, M., 2006. Cost-minimization analysis for Portugal of five doublet chemotherapy regimens from two phase III trials in the treatment of advanced non-small cell lung cancer. *Lung Cancer.* 52(3):365-71.
- Pompen, M., Gok, M., Novák, A., van Wuijtswinkel, R., Biesma, B., Schramel, F., Stigt, J., Smit, H., Postmus, P., 2009. Direct costs associated with the disease management of patients with unresectable advanced non-small-cell lung cancer in The Netherlands. *Lung Cancer.* 64(1):110-6.
- Radzikowska, E., Glaz, P., Roszkowski, K., 2002. Lung cancer in women: age, smoking, histology, performance status, stage, initial treatment and survival. Population-based study of 20.561 cases. *Ann Oncol.* 13(7):1087-1093.

- Rajeswaran, A., Trojan, A., Burnand, B., Giannelli, M., 2008. Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials. *Lung Cancer*. 59(1):1-11.
- Reeder, C.E., 1995. Overview of Pharmacoeconomics and Pharmaceutical Outcomes Evaluations. *Am. J. Health-Syst. Pharm.* 330(3):679-686.
- Sanchez, L.A., 2005. Pharmacoeconomics: Principles, Methodes, and Applications, in Dipiro, J.T., Talbert, R.L., Yee, G.C., Matzke, G.R., Wells, B.G., Posey, M.L., *Pharmacotherapy: A Pathophysiologic Approach* 6th Ed. McGrawHill, United State.
- Schiller, J.H., Harrington, D., Belani, C.P., Langer, C., Sandler, A., Krook, J., et al. 2002. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. *N Engl J Med*. 346:92—8.
- Schwander, B., Ravera, S., Giuliani, G., Nuijten, M., Walzer, S., 2012. Cost comparison of second-line treatment options for late stage non-small-cell lung cancer: cost analysis for Italy. *Clinicoecon Outcomes Res*. 4:237-43.
- Schiller, J., Tilden, D., Aristides, M., Lees, M., Kielhorn, A., Maniadakis, N., Bhalla, S., 2004. Retrospective cost analysis of gemcitabine in combination with cisplatin in non-small cell lung cancer compared to other combination therapies in Europe. *Lung Cancer*. 43(1):101-12
- Siegel, R., Naishadham, D., Jemal, A., 2013. Cancer statistics, 2013. *CA Cancer J. Clin.* 63(1):11-30.
- Tarricone, R., 2006. Cost of Illness Analysis. What Room in Health Economics. *Health Policy*. 77(1):51-63.
- Vogenberg, F.R., 2001. *Introduction to Applied Pharmacoeconomics*. McGraw-Hill, New York.
- Walley, T., Haycox, A., Boland, A., 2004. *Pharmacoeconomics*. Elsevier Science, Spain.
- Zarogoulidis, K., Zarogoulidis, P., Darwiche, K., Boutsikou, E., Machairiotis, N., Tsakiridis, K., Katsikogiannis, N., Kougioumtzi, I., Karapantzos, I., Huang, H., Spyrtatos, D., 2013. Treatment of non-small cell lung cancer (NSCLC). *J Thorac Dis. Suppl* 4:S389-96
- Zeng, X., Peng, L., Li, J., Chen, G., Tan, C., Wang, S., Wan, X., Ouyang, L., Zhao, Z., 2013. Cost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for advanced nonsquamous non-small-cell lung cancer: estimates from the perspective of the Chinese health care system. *Clin Ther*. 35(1):54-65.